Stockreport

Revolution Medicines Announces FDA Breakthrough Therapy Designation for Zoldonrasib

Revolution Medicines, Inc.  (RVMD) 
PDF Breakthrough Therapy Designation granted to zoldonrasib for the treatment of adult patients with KRAS G12D-mutated locally advanced or metastatic non-small cell lung can [Read more]